Literature DB >> 27122662

Functional analysis and drug response to zinc and D-penicillamine in stable ATP7B mutant hepatic cell lines.

Gursimran Chandhok1, Judit Horvath1, Annu Aggarwal1, Mohit Bhatt1, Andree Zibert1, Hartmut Hj Schmidt1.   

Abstract

AIM: To study the effect of anti-copper treatment for survival of hepatic cells expressing different ATP7B mutations in cell culture.
METHODS: The most common Wilson disease (WD) mutations p.H1069Q, p.R778L and p.C271*, found in the ATP7B gene encoding a liver copper transporter, were studied. The mutations represent major genotypes of the United States and Europe, China, and India, respectively. A human hepatoma cell line previously established to carry a knockout of ATP7B was used to stably express WD mutants. mRNA and protein expression of mutant ATP7B, survival of cells, apoptosis, and protein trafficking were determined.
RESULTS: Low temperature increased ATP7B protein expression in several mutants. Intracellular ATP7B localization was significantly impaired in the mutants. Mutants were classified as high, moderate, and no survival based on their viability on exposure to toxic copper. Survival of mutant p.H1069Q and to a lesser extent p.C271* improved by D-penicillamine (DPA) treatment, while mutant p.R778L showed a pronounced response to zinc (Zn) treatment. Overall, DPA treatment resulted in higher cell survival as compared to Zn treatment; however, only combined Zn + DPA treatment fully restored cell viability.
CONCLUSION: The data indicate that the basic impact of a genotype might be characterized by analysis of mutant hepatic cell lines.

Entities:  

Keywords:  ATP7B; D-penicillamine; Mutations; Therapy; Wilson disease; Zinc

Mesh:

Substances:

Year:  2016        PMID: 27122662      PMCID: PMC4837429          DOI: 10.3748/wjg.v22.i16.4109

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  55 in total

1.  Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses.

Authors:  A B Shah; I Chernov; H T Zhang; B M Ross; K Das; S Lutsenko; E Parano; L Pavone; O Evgrafov; I A Ivanova-Smolenskaya; G Annerén; K Westermark; F H Urrutia; G K Penchaszadeh; I Sternlieb; I H Scheinberg; T C Gilliam; K Petrukhin
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

2.  Zinc monotherapy and a low-copper diet are beneficial in patients with Wilson disease after liver transplantation.

Authors:  Wang Ni; Qin-Yun Dong; Yue Zhang; Zhi-Ying Wu
Journal:  CNS Neurosci Ther       Date:  2013-10-14       Impact factor: 5.243

3.  Diverse functional properties of Wilson disease ATP7B variants.

Authors:  Dominik Huster; Angelika Kühne; Ashima Bhattacharjee; Lily Raines; Vanessa Jantsch; Johannes Noe; Wiebke Schirrmeister; Ines Sommerer; Osama Sabri; Frieder Berr; Joachim Mössner; Bruno Stieger; Karel Caca; Svetlana Lutsenko
Journal:  Gastroenterology       Date:  2012-01-10       Impact factor: 22.682

4.  A study of Wilson disease mutations in Britain.

Authors:  D Curtis; M Durkie; P Balac (Morris); D Sheard; A Goodeve; I Peake; O Quarrell; S Tanner
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

5.  High frequency of two mutations in codon 778 in exon 8 of the ATP7B gene in Taiwanese families with Wilson disease.

Authors:  L M Chuang; H P Wu; M H Jang; T R Wang; W C Sue; B J Lin; D W Cox; T Y Tai
Journal:  J Med Genet       Date:  1996-06       Impact factor: 6.318

6.  Identification and analysis of mutations of the Wilson disease gene in Chinese population.

Authors:  Z Wu; N Wang; S Murong; M Lin
Journal:  Chin Med J (Engl)       Date:  2000-01       Impact factor: 2.628

7.  Defective cellular localization of mutant ATP7B in Wilson's disease patients and hepatoma cell lines.

Authors:  Dominik Huster; Michael Hoppert; Svetlana Lutsenko; Jan Zinke; Claudia Lehmann; Joachim Mössner; Frieder Berr; Karel Caca
Journal:  Gastroenterology       Date:  2003-02       Impact factor: 22.682

8.  Correlation of ATP7B genotype with phenotype in Chinese patients with Wilson disease.

Authors:  Xiao-Qing Liu; Ya-Fen Zhang; Tze-Tze Liu; Kwang-Jen Hsiao; Jian-Ming Zhang; Xue-Fan Gu; Ke-Rong Bao; Li-Hua Yu; Mei-Xian Wang
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

9.  Distinct phenotype of a Wilson disease mutation reveals a novel trafficking determinant in the copper transporter ATP7B.

Authors:  Lelita T Braiterman; Amrutha Murthy; Samuel Jayakanthan; Lydia Nyasae; Eric Tzeng; Grazyna Gromadzka; Thomas B Woolf; Svetlana Lutsenko; Ann L Hubbard
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205

10.  Long-term effects of a combination of D-penicillamine and zinc salts in the treatment of Wilson's disease in children.

Authors:  Hong Chang; Aijing Xu; Zhihong Chen; Ying Zhang; Fei Tian; Tang Li
Journal:  Exp Ther Med       Date:  2013-02-22       Impact factor: 2.447

View more
  9 in total

1.  Disulfiram causes selective hypoxic cancer cell toxicity and radio-chemo-sensitization via redox cycling of copper.

Authors:  Kelly C Falls-Hubert; Aimee L Butler; Kai Gui; Michael Anderson; Mengshi Li; Jeffrey M Stolwijk; Samuel N Rodman; Shane R Solst; Ann Tomanek-Chalkley; Charles C Searby; Val C Sheffield; Vanessa Sandfort; Hartmut Schmidt; Michael L McCormick; Brian R Wels; Bryan G Allen; Garry R Buettner; Michael K Schultz; Douglas R Spitz
Journal:  Free Radic Biol Med       Date:  2020-02-04       Impact factor: 7.376

2.  Pharmacoproteomics pinpoints HSP70 interaction for correction of the most frequent Wilson disease-causing mutant of ATP7B.

Authors:  Mafalda Concilli; Raffaella Petruzzelli; Silvia Parisi; Federico Catalano; Francesco Sirci; Francesco Napolitano; Mario Renda; Luis J V Galietta; Diego Di Bernardo; Roman S Polishchuk
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-07       Impact factor: 12.779

3.  Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent.

Authors:  Julia Smirnova; Ekaterina Kabin; Ivar Järving; Olga Bragina; Vello Tõugu; Thomas Plitz; Peep Palumaa
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379

Review 4.  Advances in Treatment of Wilson Disease.

Authors:  Annu Aggarwal; Mohit Bhatt
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2018-02-28

5.  Characterization of the most frequent ATP7B mutation causing Wilson disease in hepatocytes from patient induced pluripotent stem cells.

Authors:  Silvia Parisi; Elena V Polishchuk; Simona Allocca; Michela Ciano; Anna Musto; Maria Gallo; Lucia Perone; Giusy Ranucci; Raffaele Iorio; Roman S Polishchuk; Stefano Bonatti
Journal:  Sci Rep       Date:  2018-04-19       Impact factor: 4.379

6.  An αB-Crystallin Peptide Rescues Compartmentalization and Trafficking Response to Cu Overload of ATP7B-H1069Q, the Most Frequent Cause of Wilson Disease in the Caucasian Population.

Authors:  Simona Allocca; Michela Ciano; Maria Camilla Ciardulli; Chiara D'Ambrosio; Andrea Scaloni; Daniela Sarnataro; Maria Gabriella Caporaso; Massimo D'Agostino; Stefano Bonatti
Journal:  Int J Mol Sci       Date:  2018-06-27       Impact factor: 5.923

7.  Human Embryonic Stem Cell-Derived Wilson's Disease Model for Screening Drug Efficacy.

Authors:  Dongkyu Kim; Su-Bin Kim; Jung Lim Ryu; Heesu Hong; Jin-Hyuk Chang; Tack-Jin Yoo; Xiong Jin; Han-Jin Park; Choongseong Han; Beom Hee Lee; Jin-Ho Choi; Han-Wook Yoo; Jong-Hoon Kim; Dong-Hun Woo
Journal:  Cells       Date:  2020-04-02       Impact factor: 6.600

Review 8.  Crossroads between membrane trafficking machinery and copper homeostasis in the nerve system.

Authors:  Meng-Hsuan Wen; Xihong Xie; Pei-San Huang; Karen Yang; Tai-Yen Chen
Journal:  Open Biol       Date:  2021-12-01       Impact factor: 6.411

9.  Functional Characterization of Novel ATP7B Variants for Diagnosis of Wilson Disease.

Authors:  Sarah Guttmann; Friedrich Bernick; Magdalena Naorniakowska; Ulf Michgehl; Sara Reinartz Groba; Piotr Socha; Andree Zibert; Hartmut H Schmidt
Journal:  Front Pediatr       Date:  2018-04-30       Impact factor: 3.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.